Erkang Pharmaceutical recently received the Chemical Active Pharmaceutical Ingredient Marketing Authorization Approval Notice for sodium hydroxide API issued by the National Medical Products Administration. The approval is valid until May 11, 2031, and authorizes the company to manufacture this product domestically. Sodium hydroxide is a pH adjuster. This approval will further enrich the company's API portfolio, enhance market competitiveness, and have a positive impact on future market expansion and sales.
Hunan Er Kang PharmaceuticalNMPA approval for sodium hydroxide API enables domestic manufacturing, enriching portfolio and competitiveness.